


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Obicetrapib and obicetrapib-ezetimibe for treating primary heterozygous hypercholesterolaemia or dyslipidaemia ID6519

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Menarini (obicetrapib, obicetrapib–	All Wales Therapeutics and Toxicology
ezetimibe)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Blood Pressure UK	Wales
Cardiac Risk in the Young	British National Formulary
Cardiovascular Care Partnership	Care Quality Commission
Circulation Foundation	Department of Health - Northern Ireland
Different Strokes	Healthcare Improvement Scotland
Gene People	Medicines and Healthcare products
Genetic Alliance UK	Regulatory Agency
HEART UK	National Association of Primary Care
Metabolic Support UK	National Pharmacy Association
Pulmonary Hypertension Association	NHS Confederation
UK	NHS Wales Joint Commissioning
Pumping Marvellous Foundation	Committee
Somerville Foundation	Scottish Medicines Consortium
South Asian Health Foundation	Welsh Government
Specialised Healthcare Alliance	
Stroke Association	Possible comparator companies
	Amarox (atorvastatin, rosuvastatin)
Healthcare professional groups	Amgen (evolocumab)
Association of Genetic Nurses &	Aspire Pharma (fluvastatin)
Counsellors	Aurobindo Pharma - Milpharm
British and Irish Hypertension Society	(atorvastatin, ezetimibe, pravastatin,
British Association for the Study of the	rosuvastatin, simvastatin)
Liver	Biocon Pharma (rosuvastatin)
British Association for Nursing in Cardiavascular Care	Brown & Burk (atorvastatin, secure at a simulatatin)
Cardiovascular Care	rosuvastatin, simvastatin)
British Association of Endocrine and Thursid Surgeons	Daiichi Sankyo (bempedoic acid) Da Baddida Labaratariaa (atamaatatin)
Thyroid Surgeons	Dr. Reddy's Laboratories (atorvastatin) Flaming a Pharma (atom satatin)
British Atherosclerosis Society British Cardiavascular Society	Flamingo Pharma (atorvastatin)
British Cardiovascular Society British Diotatic Association	Glenmark Pharmaceuticals Europe (azatimiha, rasuvastatia)
British Dietetic Association	(ezetimibe, rosuvastatin)
British Heart Foundation	



Provisional Consultees

- British Inherited Metabolic Disease Group
- British Nuclear Cardiology Society
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- British Society for Haematology
- British Society for Haemostasis and Thrombosis
- British Society for Heart Failure
- British Society for Paediatric Endocrinology and Diabetes
- British Society of Cardiovascular Imaging
- British Thoracic Society
- Clinical Leaders of Thrombosis
- National Heart and Lung Institute
- National Metabolic Biochemistry Network
- Neonatal and Paediatric Pharmacists
 Group
- Primary Care Cardiovascular Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science & Technology
- Society for Endocrinology
- Society for Vascular Nurses
- Society for Vascular Technology
- TREND UK
- UK Clinical Pharmacy Association
- Vascular Society of Great Britain & Ireland

Others

- Department of Health and Social Care
- NHS England

Provisional Commentators (no right to submit or appeal)

- Krka (atorvastatin, ezetimibe, rosuvastatin)
- MSN Laboratories Europe (atorvastatin, rosuvastatin)
- Mylan (atorvastatin)
- Novartis (inclisiran)
- Novumgen (rosuvastatin)
- Organon Pharma (ezetimibe, simvastatin)
- Ranbaxy (atorvastatin, rosuvastatin, simvastatin)
- Rivopharm (ezetimibe)
- Rosemont Pharmaceuticals (atorvastatin, simvastatin)
- Sandoz (atorvastatin, ezetimibe, fluvastatin, rosuvastatin, simvastatin)
- Sanofi (alirocumab)
- Thame Laboratories (rosuvastatin)
- Upjohn (atorvastatin)
- Zentiva (atorvastatin, ezetimibe, rosuvastatin)


Relevant research groups

- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Department, Barts
- Cochrane Heart, Stroke and Circulation Thematic Group
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Centre for Cardiovascular Preventions and Outcomes
- National Institute for Cardiovascular Outcomes Research
- National Institute for Health Research
- Wellcome Trust

Associated Public Health groups

- Public Health Wales
- UK Health Security Agency

Provisional stakeholder list for the evaluation of obicetrapib and obicetrapib—ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia ID6519 Issue date: November 2025



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.